243 related articles for article (PubMed ID: 11720279)
1. The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
Becker C; Noldus J; Diamandis E; Lilja H
Crit Rev Clin Lab Sci; 2001 Oct; 38(5):357-99. PubMed ID: 11720279
[TBL] [Abstract][Full Text] [Related]
2. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
3. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
Magklara A; Scorilas A; Catalona WJ; Diamandis EP
Clin Chem; 1999 Nov; 45(11):1960-6. PubMed ID: 10545066
[TBL] [Abstract][Full Text] [Related]
4. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
[TBL] [Abstract][Full Text] [Related]
5. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
[TBL] [Abstract][Full Text] [Related]
6. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
7. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
[TBL] [Abstract][Full Text] [Related]
8. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
[TBL] [Abstract][Full Text] [Related]
9. [PSA and hK2 in the diagnosis of prostate cancer].
Alapont Alacreu JM; Navarro Rosales S; Budía Alba A; España Furió F; Morera Martínez F; Jiménez Cruz JF
Actas Urol Esp; 2008 Jun; 32(6):575-88. PubMed ID: 18655340
[TBL] [Abstract][Full Text] [Related]
10. Human Kallikrein-2, Prostate Specific Antigen and Free- Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients.
Bachour DM; Chahin E; Al-Fahoum S
Asian Pac J Cancer Prev; 2015; 16(16):7085-8. PubMed ID: 26514494
[TBL] [Abstract][Full Text] [Related]
11. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
Steuber T; Vickers AJ; Haese A; Becker C; Pettersson K; Chun FK; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
Int J Cancer; 2006 Mar; 118(5):1234-40. PubMed ID: 16152616
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease.
Ylikoski A; Pettersson K; Nurmi J; Irjala K; Karp M; Lilja H; Lövgren T; Nurmi M
Clin Chem; 2002 Aug; 48(8):1265-71. PubMed ID: 12142383
[TBL] [Abstract][Full Text] [Related]
13. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
[TBL] [Abstract][Full Text] [Related]
14. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity.
Finlay JA; Evans CL; Day JR; Payne JK; Mikolajczyk SD; Millar LS; Kuus-Reichel K; Wolfert RL; Rittenhouse HG
Urology; 1998 May; 51(5):804-9. PubMed ID: 9610595
[TBL] [Abstract][Full Text] [Related]
15. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen.
Nam RK; Diamandis EP; Toi A; Trachtenberg J; Magklara A; Scorilas A; Papnastasiou PA; Jewett MA; Narod SA
J Clin Oncol; 2000 Mar; 18(5):1036-42. PubMed ID: 10694554
[TBL] [Abstract][Full Text] [Related]
16. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
Steuber T; Niemela P; Haese A; Pettersson K; Erbersdobler A; Felix Chun KH; Graefen M; Kattan MW; Huland H; Lilja H
Prostate; 2005 Apr; 63(1):13-8. PubMed ID: 15378521
[TBL] [Abstract][Full Text] [Related]
17. Development of sensitive immunoassays for free and total human glandular kallikrein 2.
Väisänen V; Eriksson S; Ivaska KK; Lilja H; Nurmi M; Pettersson K
Clin Chem; 2004 Sep; 50(9):1607-17. PubMed ID: 15247158
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection.
Stephan C; Jung K; Soosaipillai A; Yousef GM; Cammann H; Meyer H; Xu C; Diamandis EP
BJU Int; 2005 Sep; 96(4):521-7. PubMed ID: 16104903
[TBL] [Abstract][Full Text] [Related]
19. [Serum markers for early detection and staging of prostate cancer. Status report on current and future markers].
Haese A; Graefen M; Palisaar J; Huland E; Huland H
Urologe A; 2003 Sep; 42(9):1172-87. PubMed ID: 14504750
[TBL] [Abstract][Full Text] [Related]
20. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
